Medicus Pharma Clarifies Skinject Trial, Advances Toward Next Phase in Skin Cancer

Medicus Pharma (NASDAQ: MDCX) provided a key update on its Phase 2 Skinject clinical trial, reaffirming strong results in the treatment of basal cell carcinoma. The highest-performing dose demonstrated 73% clinical clearance and 40% histological response, supporting the therapy’s potential as a non-surgical alternative for skin cancer treatment.

The company also clarified that earlier confusion around a device-only group does not impact the core results, keeping focus on the active treatment arms. Medicus now plans to advance its lead dose into the next phase, including FDA discussions and potential registrational studies.

#MedicusPharma
#MDCX
#Biotech
#SkinCancer
#BasalCellCarcinoma
#ClinicalTrials
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Oncology
#Microneedle
#Pharmaceuticals
#BiotechInvesting
#AnnaBerry
#NewsOut